REDWOOD CITY, Calif. and WUHAN, China, Sept. 17, 2020 (GLOBE NEWSWIRE) -- XWPharma (formerly XW Laboratories), a biopharmaceutical company dedicated to the discovery and development of therapeutics that apply novel platform chemistry to time-regulated neurobiology, today announced it completed a $40 million Series C financing. The financing was led by Panacea Venture, with participation from existing investors, Johnson & Johnson Innovation – JJDC, Inc., WI Harper Group, WuXi AppTec’s Corporate Venture Fund and KTB Network, and new investors, CDIB Yida Healthcare Fund, Hontai Capital and Trinity Fund.
